04.10.2018 • NewsCRB GroupBiotechnologyPharma

CRB Expands Presence in Europe

CRB Expands Presence in Europe
CRB Expands Presence in Europe

Swiss-based CRB Group, a provider of design and consulting services for the life science sector, has opened an office in Stuttgart, Germany. The office, the company’s second in Europe, supports the growing need for experts in project execution to support the pharmaceutical and biotechnology industry in the region, CRB said.

“The opening of operations for CRB in Germany strategically aligns with our clients’ growth in the region over the last decade and allows us to serve their needs locally,” said CRB president, Ryan Schroeder. “In addition, Germany’s commitment to research and manufacturing in the life science industry makes it a natural fit for the expertise of our team.”

The company has also hired Bernd Müller as the project team leader in Stuttgart. Muller previously worked at M+W group in Stuttgart, where he was the head of process department for the Bioprocess Facilities business unit. CRB said the Stuttgart office and its headquarters in Basel, Switzerland will continue to focus on life science projects in Europe. The privately held company serves markets including biotechnology, pharmaceuticals, science and technology, and food and beverage.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.